FDA — authorised 14 February 1994
- Application: NDA020233
- Marketing authorisation holder: ASTRAZENECA
- Local brand name: RHINOCORT
- Indication: AEROSOL, METERED — NASAL
- Status: approved
🇺🇸 Rhinocort in United States
FDA authorised Rhinocort on 14 February 1994 · 2,807 US adverse-event reports
Marketing authorisations
FDA — authorised 1 October 1999
- Application: NDA020746
- Marketing authorisation holder: KENVUE BRANDS
- Local brand name: RHINOCORT
- Indication: SPRAY, METERED — NASAL
- Status: approved
FDA
- Status: approved
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 2,807
Most-reported reactions
- Dyspnoea — 432 reports (15.39%)
- Drug Ineffective — 327 reports (11.65%)
- Asthma — 326 reports (11.61%)
- Headache — 308 reports (10.97%)
- Nausea — 249 reports (8.87%)
- Pain — 245 reports (8.73%)
- Cough — 236 reports (8.41%)
- Dizziness — 233 reports (8.3%)
- Malaise — 226 reports (8.05%)
- Fatigue — 225 reports (8.02%)
Rhinocort in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in United States
Frequently asked questions
Is Rhinocort approved in United States?
Yes. FDA authorised it on 14 February 1994; FDA authorised it on 1 October 1999; FDA has authorised it.
Who is the marketing authorisation holder for Rhinocort in United States?
ASTRAZENECA holds the US marketing authorisation.